leadf
logo-loader
viewCanntab Therapeutics Ltd

Canntab Therapeutics closes $1M purchase of cannabis-processing equipment and leasehold improvements from CMAX Technologies

Canntab also closed a $300,000 deal with Pharmagenerics Solutions to purchase cannabis-processing equipment 

Canntab Therapeutics Ltd - Canntab Therapeutics Limited closes $1 million purchase of cannabis-processing equipment and leasehold improvements from CMAX Technologies Inc in Ontario
Canntab is focused on the manufacturing and distribution of hard pill cannabinoid formulations in multiple doses and timed-release combinations

Canntab Therapeutics Limited (CSE:PILL) (OTCQB:CTABF) has closed on the $1,018,000 purchase of cannabis-processing equipment and leasehold improvements from CMAX Technologies Inc in Ontario.  

In a statement Tuesday, Canntab said the purchase price was based upon third-party valuations it had ordered.  

The purchase price was satisfied through the issuance of 1,996,078 common shares of the company at $0.51 each. A deposit of 200,000 shares was paid to CMAX shortly after the execution of the asset purchase agreement. 

READ: Canntab Therapeutics wins its first US patent covering its multi-layer tablet cannabinoid formulations

Canntab also said it closed its binding asset purchase agreement with Pharmagenerics Solutions Inc (Pharma) to purchase cannabis-processing equipment. 

The purchase price of those assets was $300,000, satisfied through the issuance of 588,235 shares at $0.51 each. Joshi Laxminarayan, Canntab’s chief scientific officer, is the sole officer, director and shareholder of Pharma.

According to Canntab, CFO Richard Goldstein, President Jeffrey Renwick, Secretary Barry Polisuk and Laxaminarayan are shareholders of CMAX Technologies.

Polisuk holds 1.44% of CMAX's outstanding common shares; Goldstein 11.19%; Renwick 38.83%; and Laxminarayan 18.04%.

Canntab, based in Ontario, is focused on the manufacturing and distribution of a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations. It holds a Cannabis Standard Processing & Sales for Medical Purposes Licence, a Cannabis Research Licence, and an Industrial Hemp Licence from Health Canada.

The company is also in the process of establishing a CBD manufacturing and distribution business in the US, through its wholly-owned US subsidiary.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

 

Quick facts: Canntab Therapeutics Ltd

Price: 0.72 CAD

CSE:PILL
Market: CSE
Market Cap: $23.81 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Canntab Therapeutics Ltd named herein, including the promotion by the Company of Canntab Therapeutics Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Canntab Therapeutics hits major milestone as company makes first delivery to...

Canntab Therapeutics (CSE: PILL- OTCQB: CTABF) CEO Larry Latowski and CFO Richard Goldstein joined Steve Darling from Proactive with news the company has completed its first delivery of two of five SKU's ordered by MediPharm Labs. Goldstein and Latowski tall about them taking this major step...

3 days, 10 hours ago

2 min read